What is the Treatment of Gastrointestinal Luminal Tuberculosis?
Gastrointestinal luminal tuberculosis (intestinal TB, ITB) is a treatable infection of the GI tract that requires a full, structured course of antitubercular therapy. Management follows a phased regimen with defined clinical monitoring endpoints to confirm treatment response.
Treatment Approach
Patients with abdominal TB require a complete antitubercular regimen. The standard approach involves two sequential treatment phases — an initial intensive phase followed by a continuation phase. The specific drug selection, phasing, and duration are detailed in the full protocol.
Monitoring & Clinical Goals
Response to therapy is assessed weekly over 4–6 weeks. Key indicators of adequate response include resolution of symptoms, weight gain, improving hemoglobin, and a fall in C-reactive protein (CRP) levels.
References
- Patients with abdominal TB should receive a full course of antitubercular therapy.
- A 2-month course of treatment as detailed in Table 8 is currently recommended for uncomplicated ITB.
- Monitoring of the response should be carried out weekly for 4–6 weeks.
- Improving hemoglobin and a fall in C-reactive protein (CRP) levels are more sensitive than a fall in the erythrocyte sedimentation rate (ESR) in determining the response to TB therapy.